Fares Rabadi v. Usdea

122 F.4th 371
CourtCourt of Appeals for the Ninth Circuit
DecidedNovember 27, 2024
Docket22-70114
StatusPublished
Cited by2 cases

This text of 122 F.4th 371 (Fares Rabadi v. Usdea) is published on Counsel Stack Legal Research, covering Court of Appeals for the Ninth Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Fares Rabadi v. Usdea, 122 F.4th 371 (9th Cir. 2024).

Opinion

FOR PUBLICATION

UNITED STATES COURT OF APPEALS FOR THE NINTH CIRCUIT

FARES JERIES RABADI, M.D., No. 22-70114

Petitioner, DEA No. v. 20-14

U.S. DRUG ENFORCEMENT ADMINISTRATION; MERRICK B. OPINION GARLAND, Attorney General; ANNE MILGRAM, Administrator, Drug Enforcement Administration,

Respondents.

On Petition for Review of an Order of the Drug Enforcement Agency

Argued and Submitted November 12, 2024 San Francisco, California

Filed November 27, 2024

Before: Sidney R. Thomas and Eric D. Miller, Circuit Judges, and Donald W. Molloy,* District Judge.

Opinion by Judge Sidney R. Thomas

* The Honorable Donald W. Molloy, United States District Judge for the District of Montana, sitting by designation. 2 RABADI V. USDEA

SUMMARY**

Drug Enforcement Administration

The panel denied a petition for review of the Drug Enforcement Administration (“DEA”) Administrator’s final order revoking Dr. Fares Jeries Rabadi’s certificate of registration to dispense controlled substances. Rabadi argued that the DEA’s revocation of his registration was invalid because DEA administrative law judges are unconstitutionally insulated from removal by two layers of “for-cause” protections. The panel held that Rabadi’s argument failed under Decker Coal Co. v. Pehringer, 8 F.4th 1123 (9th Cir. 2021) (holding that the Department of Labor ALJ removal protections are constitutional). First, DEA ALJs perform purely adjudicatory functions just like Department of Labor ALJs. Second, Congress does not mandate that the DEA use ALJs as presiding officers for administrative hearings. Third, DEA ALJ decisions are reviewed de novo by the DEA Administrator. The panel rejected Rabadi’s argument that the DEA Administrator’s order was arbitrary and capricious. The Administrator properly ignored Rabadi’s defense that high dosages of prescribed drugs could still be safe, and the Administrator’s decision to find Rabadi’s lack of a conviction record not dispositive was not arbitrary or capricious.

** This summary constitutes no part of the opinion of the court. It has been prepared by court staff for the convenience of the reader. RABADI V. USDEA 3

COUNSEL

Joshua S. Lowther (argued) and Bingzi Hu, Lowther Walker LLC, Atlanta, Georgia, for Petitioner. Anita J. Gay (argued) and Brendan J. McDonald, Trial Attorneys, Narcotic and Dangerous Drug Section; Kenneth A. Polite Jr., Assistant Attorney General; Nicole M. Argentieri, Principal Deputy Assistant Attorney General, Head of Criminal Division; United States Department of Justice, Washington, D.C.; for Respondents.

OPINION

THOMAS, Circuit Judge:

Dr. Fares Jeries Rabadi petitions for review of the Drug Enforcement Administration (“DEA”) Administrator’s final order revoking his certificate of registration to dispense controlled substances. The DEA Administrator had jurisdiction to revoke Rabadi’s registration under 21 U.S.C. § 824(a)(4).1 We have jurisdiction to review the DEA’s final order under 21 U.S.C. § 877. We deny Rabadi’s petition for review. “We review questions of constitutional law de novo.” Decker Coal Co. v. Pehringer, 8 F.4th 1123, 1129 (9th Cir. 2021). We must set aside an agency decision that is “arbitrary, capricious, an abuse of discretion, or otherwise not in accordance with law.” 5 U.S.C. § 706(2)(A). A decision “based on a consideration of relevant factors” and

1 The Attorney General delegated this statutory authority to the DEA Administrator. 28 C.F.R. § 0.100(b). 4 RABADI V. USDEA

with “no clear error of judgment” is not arbitrary or capricious. Fry v. DEA, 353 F.3d 1041, 1043 (9th Cir. 2003). I Rabadi has been a licensed physician in California since 1998. In April 2018, the DEA initiated an investigation into Rabadi after being alerted to his high-risk prescribing practices of controlled substances. In March 2020, the DEA issued an Order to Show Cause and Immediate Suspension of Registration stating that Rabadi’s continued registration to dispense controlled substances would be inconsistent with the public interest as defined by the Controlled Substances Act. See 21 U.S.C. §§ 823(g)(1),2 824(a)(4). The agency alleged Rabadi “violated federal and California law” by “issuing numerous prescriptions for . . . controlled substances outside the usual course of professional practice and not for a legitimate medical purpose to seven individuals.” Rabadi requested a hearing before an administrative law judge (“ALJ”), which occurred in September 2020. At the hearing, the government’s expert witness testified that Rabadi failed to conduct adequate examinations or keep adequate medical records and prescribed high dosages of controlled substances, often in dangerous combinations. Rabadi testified that he acted within the standard of care. He explained the lack of documentation in his records by

2 The version of the statute that was in effect at the time of Rabadi’s proceedings listed the public interest factors at 21 U.S.C. § 823(f). Section 823(f) was re-designated as § 823(g)(1) as part of an amendment effective December 2, 2022. Medical Marijuana and Cannabidiol Research Expansion Act, Pub. L. No. 117-215, 136 Stat. 2257 (2022). The language itself has not changed. RABADI V. USDEA 5

saying, “I rely on my photographic memory.” Addressing the dosages he prescribed, Rabadi said his patients would “not overdose” because “all the study dosages . . . were five- six times more than the FDA-approved dose.” The ALJ sustained an objection to Rabadi’s discussion of “study dosages” on the grounds that “tangential reports” were outside the scope of the hearing. Rabadi did not raise the “study dosages” again or elaborate further. The ALJ issued his Recommended Rulings, Findings of Fact, Conclusions of Law, and Decision in December 2020. The ALJ found Rabadi’s testimony not credible and recommended revoking his registration. The DEA Administrator published a final Decision and Order in the Federal Register on May 19, 2022, adopting the ALJ’s recommendations with minor modifications. The Administrator revoked Rabadi’s registration as inconsistent with the public interest under 21 U.S.C. §§ 823(g)(1) and 823(a)(4). Rabadi petitioned for review. II Rabadi argues that the DEA’s revocation of his registration is invalid because DEA ALJs are unconstitutionally insulated from removal by two layers of “for-cause” protections.3 For hearings before the DEA, the Administrator appoints an ALJ as a presiding officer. 21 C.F.R. §§ 1316.42(f), 1316.52.4 The ALJ is removable only

3 Although Rabadi did not challenge the ALJ’s removal restrictions in the agency proceedings below, he was not required to do so because the agency had “no special expertise” over his “purely constitutional claim[]” and would not be “capable of remedying any defects” in the removal scheme. Carr v. Saul, 593 U.S.

Related

Care One, LLC v. NLRB
Second Circuit, 2026
Stephen McCarthy v. DEA
Third Circuit, 2025

Cite This Page — Counsel Stack

Bluebook (online)
122 F.4th 371, Counsel Stack Legal Research, https://law.counselstack.com/opinion/fares-rabadi-v-usdea-ca9-2024.